Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Theranostics in immuno-oncology using nanobody derivatives.
Lecocq Q, De Vlaeminck Y, Hanssens H, D'Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Lecocq Q, et al. Among authors: hanssens h. Theranostics. 2019 Oct 15;9(25):7772-7791. doi: 10.7150/thno.34941. eCollection 2019. Theranostics. 2019. PMID: 31695800 Free PMC article. Review.
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K, Morgenstern A, Bruchertseifer F, Lahoutte T, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Among authors: hanssens h. Cancers (Basel). 2020 Apr 21;12(4):1017. doi: 10.3390/cancers12041017. Cancers (Basel). 2020. PMID: 32326199 Free PMC article.
The antigen-binding moiety in the driver's seat of CARs.
Hanssens H, Meeus F, De Veirman K, Breckpot K, Devoogdt N. Hanssens H, et al. Med Res Rev. 2021 May 24. doi: 10.1002/med.21818. Online ahead of print. Med Res Rev. 2021. PMID: 34028069 Review.
The road to personalized myeloma medicine: Patient-specific single-domain antibodies for anti-idiotypic radionuclide therapy.
Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Among authors: hanssens h. Mol Cancer Ther. 2021 Oct 19:molcanther.MCT-21-0220-A.2021. doi: 10.1158/1535-7163.MCT-21-0220. Online ahead of print. Mol Cancer Ther. 2021. PMID: 34667109